Sift Biosciences
Develops next-generation peptide immunotherapy platform using AI metagenomics and high-throughput profiling to engage memory T cells for cancer and autoimmune diseases
$3.7MPre-Seed
Role not disclosedEI
Eisai Innovation
Activity from announced rounds
Activity in this selectionsimplyhealth-ventures-98030ada
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $3.7M 1 disclosed · full round size, not this investor’s share